Chemistry Experimental General Procedures:
Reactions were carried out under inert conditions using an atmosphere of nitrogen, anhydrous solvents and oven dried glassware, unless aqueous reagents were used or otherwise stated. Microwave reactions were carried out using a Biotage ® Initiator Classic microwave synthesiser.
Anhydrous solvents were dried by passing over an activated alumina column, under an inert atmosphere, using a solvent purification system. Water was purified by an Elix ® UV-10 system. All other solvents and reagents were used as supplied (analytical or HPLC grade) without prior purification. PE refers to the fraction of petroleum ether boiling in the range 30-40 . rt refers to room temperature. Aqueous solutions of ammonium chloride (NH 4 Cl) and sodium bicarbonate (NaHCO 3 ) were saturated. Concentration of solvents in vacuo was achieved by rotary evaporation using a diaphragm pump. Purification by flash column chromatography was carried out using Kieselgel 60 and a positive solvent pressure.
Analytical procedures:
TLC was carried out using Merck Kieselgel 60 F254 plates which were visualised using UV light (254 nm). Melting points were recorded on a EZ-Melt automated melting point apparatus. Fourier transform IR spectroscopy was carried out using a Bruker Tensor 27 FT-IR spectrometer as neat samples or thin films. Wavelengths of peak absorption are given in wavenumbers (cm -1 ), with broad (br) signals indicated.
NMR spectra were recorded using Bruker Advance spectrometers (AVII 400 or AVII 500). 1 H NMR spectra were recorded at 298 K, locked to the relevant solvent standard. 1 H NMR and 13 C NMR data were recorded at 298 K, locked to the relevant solvent standard. NMR data are presented as: chemical shift " (in ppm, " TMS = 0), multiplicity (s = singlet, d = doublet, t = triplet, q =quartet, m = multiplet, br = broad, obs = obscured), coupling constants (J in Hz) and integration. Proton peak assignments were based on 1D data and COSY analysis and carbon peak assignments were based on 1D data and HSQC and HMBC analysis. Low resolution mass spectroscopy was carried out on an Agilent 6120 mass spectrometer. Accurate mass measurements were run on either a Bruker MicroTOF internally calibrated with polyalanine, or a Micromass GCT instrument fitted with a Scientific Glass Instruments BPX5 column (15 m ◊ 0.25 mm) using amyl acetate as a lock mass. HR ESI and APCI were run on a Waters Acquity Ultraperformance LC system coupled to a Thermo Orbitrap Exactive MS. Optical rotations were recorded on a Perkin-Elmer PE241 polarimeter with a water-jacketed 1 cm cell. Specific rotations are reported in 10 -1 deg cm 2 g -1 and concentrations in g/100 mL.
Chemical Experimental Procedures and Data:
General Procedure A:
Benzoxazole ring closure from a benzoic acid and 2-aminophenol derivative To a suspension of the benzoic acid derivative (1 eq.) in CH 2 Cl 2 at 0 was added thionyl chloride (3 eq.) and dimethylformamide (cat.) The reaction mixture was warmed to rt and stirred for 16 h. When the reaction was complete, the reaction mixture was concentrated in vacuo, dissolved in Et 2 O and filtered. The filtrate was concentrated in vacuo to yield the acid chloride, which was used immediately without further purification.
To a suspension of the 2-aminophenol derivative (1 eq.) in 1,4-dioxane was added a solution of the prepared acid chloride (1 eq.) in 1,4-dioxane at rt. The reaction vessel was heated under microwave activation at 210 for 15 min, then cooled to rt. The reaction mixture was poured into NaOH solution (1 M aq.), and extracted with EtOAc three times. The combined organic fractions were dried (Na 2 SO 4 ) and concentrated in vacuo to yield the crude benzoxazole product.
General procedure B:
Formation of benzoxazole carboxamides NHMeOMe O Acid benzoxazole derivatives were obtained by following General Procedure A, with no further purification. To a solution of the crude acid (1 eq.) in DMF was added EDC hydrochloride (2 eq.), N,O-dimethylhydroxylamine hydrochloride (2 eq.) and NEt 3 (2 eq.). The reaction mixture was stirred at rt for 16 h, then concentrated in vacuo. The residue was dissolved in EtOAc, then washed with citric acid solution (10% aq.), NaHCO 3 solution(10% aq.) and brine. The organic layer was concentrated in vacuo to yield the crude carboxamide product.
General procedure C:
Formation of trifluoromethylketone oximes from carboxamides Adapting a known procedure, [10] caesium fluoride (0.2 eq.) and trifluoromethyltrimethylsilane (2 eq.) were added to a solution of Weinreb amide derivative (1 eq.) in toluene. The reaction mixture was stirred at rt with further equivalents of caesium fluoride and trifluoromethyltrimethylsilane added every 24 h until the reaction was complete by TLC. At this point, the reaction was concentrated in vacuo and the residue dissolved in THF. TBAF (1.2 eq., 1 M in THF) was added dropwise and the reaction stirred at rt for 3 h at 50 . The reaction was cooled to rt, diluted with Et 2 O and washed with water and brine. The organic layer was dried (Na 2 SO 4 ) and concentrated in vacuo to yield the crude trifluoromethyl ketone product. The crude was filtered through a silica plug, eluting with PE : EtOAc (2:1), and concentrated in vacuo.
To a solution of the prepared crude trifluoromethylketone derivative (1 eq.) in pyridine (excess) and ethanol over molecular sieves (3 Å) was added hydroxylammonium chloride (3 eq.). The reaction mixture was heated under reflux for 16 h, then concentrated in vacuo. The residue was dissolved in EtOAc, washed with brine/water (1:1), dried (Na 2 SO 4 ) and concentrated in vacuo to yield the crude oxime product.
General procedure D:
Formation of trifluoromethylketone tosyl oximes To a solution of oxime (1 eq.), 4-dimethylaminopyridine (0.1 eq.) and triethylamine (3 eq.) in CH 2 Cl 2 was added p-toluenesulfonyl chloride (2 eq., recrystallised from PE) portionwise. The reaction mixture was stirred at 40°C for 16 h, then cooled to rt. The mixture was diluted with CH 2 Cl 2 , washed with water then brine, dried (Na 2 SO 4 ) and concentrated in vacuo to yield the crude tosyl oxime products in a mixture of E/Z isomers.
General procedure E:
Formation of the diaziridine −78 °C NH 3 (excess) was condensed into a solution of tosyl oxime (1 eq.) in CH 2 Cl 2 at ≠78 . The reaction mixture was stirred and warmed to rt over 6 h, then concentrated in vacuo to yield the crude diaziridine product.
General procedure F:
Formation of the diazirine To a solution of diaziridine (1 eq.) and triethylamine (3 eq.) in CH 2 Cl 2 was added iodine (1.2 eq.) portionwise. The reaction mixture was covered in foil to exclude light and stirred for 15 min at rt. The mixture was then concentrated in vacuo to yield the crude diazirine product.
General procedure G:
Sonagashira coupling of aryl halide with TMS-acetylene To a solution of aryl halide (1 eq.), bis(triphenylphosphine)palladium(II) dichloride (0.15 eq.) and copper (I) iodide (0.1 eq.) in THF was added NEt 3 (excess) and trimethylsilylacetylene (1 eq.) dropwise. The reaction mixture was degassed, put under a N 2 atmosphere, and stirred at 70 until the reaction was complete by TLC. The solvent was removed in vacuo and the residue purified by flash column chromatography. The isolated TMS-alkyne intermediate was dissolved in THF and TBAF (1.5 eq., 1 M in THF) was added dropwise. The reaction was stirred at rt until completion. The reaction mixture was diluted with EtOAc, washed with water and the phases separated. The organic layer was dried (Na 2 SO 4 ) and concentrated in vacuo to yield the crude alkyne product. Carboxamide 9 was obtained according to General Procedure B, using 3-iodobenzoic acid (486 mg, 1.96 mmol), thionyl chloride (0.43 mL, 5.88 mmol) and DMF (0.10 mL) in CH 2 Cl 2 (20 mL). The acid chloride intermediate formed was reacted with 3-amino-4-hydroxybenzoic acid (300 mg, 1.96 mmol) in 1,4-dioxane (5 mL). Amide coupling was performed on the crude product using EDC hydrochloride (752 mg, 3.92 mmol) , N,O-dimethylhydroxylamine hydrochloride (382 mg, 3.92 mmol) and NEt 3 (0.60 mL, 4.31 mmol) in DMF (25 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 7:3) to yield carboxamide 9 (392 mg, 0.960 mmol, 49%) as a white solid. R f 0.21 (PE : EtOAc, 7:3); v max (cm -1 ) 1635 ((C=O)NH), 1450, 1107 (C-N), 1085; mp 113-115 ; 1 HNMR (400 MHz, CDCl 3 ) " H 8.62 (1H, dd, J = 1.3, 1.3 Hz, H 2' ), 8.22 (1H, ddd, J = 7.8, 1.3, 1.3 Hz, H 6' ), 8.15 (1H, d , J = 1.7 Hz, H 6 ), 7.88 (1H, 1H, ddd, J = 7.8, 1.3, 1.3 Hz, H 4' ), 7.77 (1H, dd, J = 8.5, 1.7 Hz, H 2 ), 7.61 (1H, d, J = 8.5 Hz, H 3 ), 7.27 (1H, dd, J = 7.8, 7.8 Hz, H 5' ), 3.57 (3H, s, H 10 ), 3.41 (3H, s, H 9 ); 13 CNMR (125 MHz, CDCl 3 ) " C 169.2 (C 8 ), 162.5 (C 7 ), 152.1 (C 4 ), 141.6 (C 4' ), 140.8 (C 5 ), 136.6 (C 2' ), 131.0 (C 1 ), 130.7 (C 5' ), 128.8 (C 1' ), 126.9 (C 6' ), 126.6 (C 2 ), 120.8 (C 6 ), 110.5 (C 3 ), 94.5 (C 3' ), 61.3 (C 10 ), 33.9 (C 9 ); HRMS (APCI + ) Calc. Oxime 10 was obtained according to General Procedure C, using carboxamide 9 (1.45 g, 3.55 mmol), trifluoromethyltrimethylsilane (1.05 mL, 7.10 mmol) and caesium fluoride (108 mg, 0.710 mmol) in toluene (40 mL). The reaction was stirred for three days, with further trifluoromethyltrimethylsilane (1.05 mL, 7.10 mmol) and caesium fluoride (108 mg, 0.710 mmol) added every 24 h. TBAF (4.26 mL, 1 M in THF) was used for desilylation of the intermediate formed. The crude trifluoromethylketone product was dissolved in pyridine (5 mL) and ethanol (25 mL) and refluxed with hydroxylammonium chloride (740 mg, 10.7 mmol). The crude product was purified by flash column chromatography (PE : EtOAc, 9:1) to yield oxime 10 (358 mg, 0.828 mmol, 23%) as a white solid. Tosyl oxime 11 was obtained according to General Procedure D, using oxime 10 (358 mg, 0.828 mmol), p-toluenesulfonyl chloride (316 mg, 1.66 mmol), 4-dimethylaminopyridine (10.1 mg, 82.8 µmol) and NEt 3 (0.35 mL, 2.48 mmol) in CH 2 Cl 2 (20 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 37:3) to yield tosyl oxime 11 (402 mg, 0.685 mmol, 83%) as a pale yellow solid in a mixture of isomers (7:1). Diaziridine 12 was obtained according to General Procedure E, using tosyl oxime 11 (375 mg, 0.640 mmol) and NH 3 (5 mL) in CH 2 Cl 2 (5 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 4:1) to yield diaziridine 12 (270 mg, 0.626 mmol, 98%) as a white solid. Diazirine 13 was obtained according to General Procedure F, using diaziridine 12 (250 mg, 0.580 mmol), iodine (176 mg, 0.696 mmol) and NEt 3 (0.24 mL, 1.74 mmol) in CH 2 Cl 2 (15 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 19:1 ae 9:1) to yield diazirine 13 (242 mg, 0.564 mmol, 97%) as a white solid. Diazirine 2 was obtained according to General Procedure G, using diazirine 13 (100 mg, 0.233 mmol), bis(triphenylphosphine)palladium(II) dichloride (24.5 mg, 35.0 µmol), copper(I) iodide (4.44 mg, 23.3 µmol), NEt 3 (0.70 mL) and trimethylsilylacetylene (40 µL, 0.280 mmol) in THF (10 mL). The reaction was complete after 1 h. The TMS-protected alkyne intermediate formed was purified by flash column chromatography (PE : EtOAc, 1:0 ae 99:1), then deprotected with TBAF (0.70 mL, 1 M in THF) in THF (5 mL). The reaction was complete after 30 min. The crude product was purified by flash column chromatography (PE : EtOAc, 1:0 ae 49:1) to yield alkyne 2 (53.2 mg, 0.163 mmol, 70%) as a white solid. R f 0.62 (PE : EtOAc, 49:1); v max (cm -1 ) 3310 (sharp, alkyne C-H), 1556, 1259 (C-F), 1197, 1154, 803; mp 105-107 ; 1 HNMR (500 MHz, CDCl 3 ) " H 8.40 (1H, dd, J = 1.7, 1.7 Hz, H 2' ), 8.25 (1H, ddd, J = 7.9, 1.4, 1.4 Hz, H 6' ), 7.75 (1H, d, J = 1.3 Hz, H 6 ), 7.70 (1H, ddd, J = 7.9, 1.4, 1.4 Hz, H 4' ), 7.64 (1H, d, J = 8.6 Hz, H 3 ), 7.54 (1H, dd, J = 7.9, 7.9 Hz, H 5' ), 7.24 (1H, dd, J = 8.6, 1.3 Hz, H 2 ), 3.20 (1H, s, H 8' ); 13 CNMR (125 MHz, CDCl 3 ) " C 163.6 (C 7 ), 151.4 (C 4 ), 142.6 (C 5 ), 135.4 (C 4' ), 131.4 (C 2' ), 129.1 (C 5' ), 127.9 (C 6' ), 126.9 (C 1' ), 125.8 (C 1 ), 123.9 (C 2 ), 123.3 (C 3' ), 122.2 (q, 1 J C-F = 274.7 Hz, C 9 ), 119.3 (C 6 ), 111.3 (C 3 ), 82.4 (C 7' ), 78.6 (C 8' ), 28.7 (q, 2 J C-F = 40. Carboxamide 14 was obtained according to General Procedure B, using 4-iodobenzoic acid (500 mg, 2.01 mmol), thionyl chloride (0.44 mL, 6.03 mmol) and DMF (0.10 mL) in CH 2 Cl 2 (20 mL). The acid chloride intermediate formed was added to a solution of 3-amino-4-hydroxybenzoic acid (277 mg, 1.81 mmol, 0.9 eq.) in 1,4-dioxane (5 mL). Amide coupling was performed on the crude product using EDC hydrochloride (769 mg, 4.02 mmol), N,O-dimethylhydroxylamine hydrochloride (392 mg, 4.02 mmol) and NEt 3 (0.56 mL, 4.01 mmol) in DMF (25 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 3:1) to yield carboxamide 14 (281 mg, 0.688 mmol, 38%) as a white solid. R f 0.11 (PE : EtOAc, 9:1); v max (cm -1 ) 2980 (C-H), 1636 ((C=O) 
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.4 (C 7 ), 152.1 (C 4 ), 141.7 (C 5 ), 138.4 (C 3' ), 130.9 (C 1 ), 129.2 (C 2' ), 126.5 (C 2 ), 126.3 (C 1' ), 120.7 (C 6 ), 110.4 (C 3 ), 99.1 (C 4' ), 61.2 (C 10 ), 33.9 (C 9 ); HRMS (ES + ) Calc. Oxime 15 was obtained according to General Procedure C, using carboxamide 14 (1.55 g, 3.81 mmol), trifluoromethyltrimethylsilane (1.13 mL, 7.62 mmol) and caesium fluoride (116 mg, 0.762 mmol) in toluene (50 mL). The reaction was stirred for three days, with further trifluoromethyltrimethylsilane (1.13 mL, 7.62 mmol) and caesium fluoride (116 mg, 0.762 mmol) added every 24 h. TBAF (4.57 mL, 1 M in THF) was used for desilylation of the intermediate formed. The crude trifluoromethylketone product was dissolved in pyridine (5 mL) and ethanol (25 mL) and refluxed after addition of hydroxylammonium chloride (794 mg, 11.4 mmol). The crude product was purified by flash column chromatography (PE : EtOAc, 9:1 ae 4:1) to yield oxime 15 (527 mg, 1.22 mmol, 32%) as a pale green solid. Tosyl oxime 16 was obtained according to General Procedure D, using oxime 15 (1.80 g, 4.17 mmol), p-toluenesulfonyl chloride (1.59 g, 8.33 mmol), 4-dimethylaminopyridine (50.9 mg, 0.417 mmol) and NEt 3 (1.73 mL, 12.5 mmol) in CH 2 Cl 2 (50 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 19:1 ae 4:1) to yield tosyl oxime 16 (1.35 g, 2.30 mmol, 55%) as a pale yellow solid in a mixture of isomers (2:1). Diaziridine 17 was obtained according to General Procedure E, using tosyl oxime 16 (1.82 g, 3.11 mmol) and NH 3 (5 mL) in CH 2 Cl 2 (25 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 4:1) to yield diaziridine 17 (1.05 g, 2.43 mmol, 78%) as a pale yellow solid. Diazirine 18 was obtained according to General Procedure F, using diaziridine 17 (580 mg, 1.35 mmol), iodine (409 mg, 1.61 mmol) and NEt 3 (0.56 mL, 4.04 mmol) in CH 2 Cl 2 (25 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 19:1 ae 9:1) to yield diazirine 18 (564 mg, 1.31 mmol, 98%) as a white solid. Diazirine 3 was obtained according to General Procedure G, using diazirine 18 (100 mg, 0.233 mmol), bis(triphenylphosphine)palladium(II) dichloride (24.5 mg, 35.0 µmol), copper(I) iodide (4.44 mg, 23.3 µmol), NEt 3 (0.70 mL) and trimethylsilylacetylene (39 µL, 0.280 mmol) in THF (10 mL). The reaction was complete after 1 h. The TMS-protected alkyne intermediate formed was purified by flash column chromatography (PE : EtOAc, 1:0 ae 49:1), then deprotected with TBAF (0.70 mL, 1 M in THF) in THF (5 mL). The reaction was complete after 30 min. The crude product was purified by flash column chromatography (PE : EtOAc, 1:0 ae 49:1) to yield alkyne 3 (38.2 mg, 0.117 mmol, 50%) as a white solid. Carboxamide 19 was obtained by a procedure based on General Procedure B except with the addition of 1-hydroxybenzotriazole in the amide coupling. 5-Bromonaphthoic acid (502 mg, 2.00 mmol), thionyl chloride (0.44 mL, 6.00 mmol) and DMF (0.10 mL) were used in CH 2 Cl 2 (20 mL). The acid chloride intermediate formed was reacted with 3-amino-4-hydroxybenzoic acid (277 mg, 1.80 mmol, 0.9 eq.) in 1,4-dioxane (5 mL). Amide coupling was performed on the crude product using EDC hydrochloride (575 mg, 3.00 mmol, 1.5 eq.), N,O-dimethylhydroxylamine hydrochloride (293 mg, 3.00 mmol, 1.5 eq.), 1-hydroxybenzotriazole (135 mg, 1.00 mmol, 0.5 eq.) and NEt 3 (0.42 mL, 3.00 mmol, 1.5 eq.) in DMF (25 mL). The crude product was purified by flash column chromatography (PE : EtOAc, 1:1) to yield carboxamide 20 (459 mg, 1.12 mmol, 62%) as a white solid. 
2-(5-Bromonaphthalen-1-yl)-N -methoxy-N -methylbenzo[d]oxazole-5-carboxamide 19
, 151.4 (C 4 ), 141.8 (C 5 ), 132.4 (C 5' ), 132.0 (C 10' ), 131.6 (C 4' ), 130.9 (C 7' ), 130.7 (C 1 ), 130.2 (C 2' ), 128.2 (C 8' ), 126.5 (C 2 ), 126.3 (C 3' ), 126.2 (C 9' ), 123.6 (C 1' or C 6' ), 123.5 (C 1' or C 6' ), 120.8 (C 6 ), 110.2 (C 3 ), 61.1 (C 10 ), 33.9 (C 9 ); HRMS (ES + ) Calc. 
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Oxime 21 was obtained according to General Procedure C, using carboxamide 22 (1.18 g, 2.87 mmol), trifluoromethyltrimethylsilane (0.85 mL, 5.74 mmol) and caesium fluoride (87.2 mg, 0.574 mmol) in toluene (40 mL). The reaction was stirred for three days, with further trifluoromethyltrimethylsilane (0.85 mL, 5.74 mmol) and caesium fluoride (87.2 mg, 0.574 mmol) added every 24 h. TBAF (3.44 mL, 1 M in THF) was used for desilylation of the intermediate formed. The crude trifluoromethylketone product was dissolved in pyridine (5 mL) and ethanol (25 mL) and refluxed with hydroxylammonium chloride (598 mg, 8.61 mmol). The crude product was purified by flash column chromatography (PE : EtOAc, 9:1) to yield oxime 21 (699 mg, 1.61 mmol, 56%) as a yellow solid. R f 0.31 (PE : EtOAc, 9:1); v max (cm -1 ) 3223 (-OH), 2981 (C-H), 1696 (C=N-OH), 1253 (C-F), 1154; mp 182-183 ; 1 HNMR (500 MHz, (CD 3 ) 2 CO) " H 11.96 (1H, br s, -OH), 9.63 (1H, ddd, J = 8.7, 1.1, 1.1 Hz, H 9' ), 8.61 (1H, dd, J = 7.4, 1.1 Hz, H 2' ), 8.57 (1H, ddd, J = 8.6, 1.1, 1.1 Hz, H 4' ), 8.06 (1H, s, H 6 ), 8.05 (1H, obs m, H 7' ), 7.81 (1H, d, J = 8.4 Hz, H 3 ), 7.76 (1H, dd, J = 8.6, 7.4 Hz, H 3' ), 7.67 (1H, dd, J = 8.7, 7.6 Hz, H 8' ), 7.65 (1H, dd, J = 8.4, 1.6 Hz, H 2 ); 13 CNMR (125 MHz, CDCl 3 ) " C 163.8 (C 7 ), 151.9 (C 8 ), 151.7 (C 4 ), 143.1 (C 5 ), 133.1 (C 1 ), 132.8 (C 5' ), 132.2 (C 10' ), 132.0 (C 4' ), 131.5 (C 7' ), 131.4 (C 2' ), 129.3 (C 8' ), 127.8 (C 3' ), 127.5 (C 2 ), 127.4 (C 9' ), 124.6 (C 1' ), 123.7 (C 6' ), 122.2 (q, 1 J C-F = 273.1 Hz, C 9 ), 121.9 (C 6 ), 111. Diaziridine 25 was obtained according to General Procedure E, using tosyl oxime 23 (630 mg, 1.07 mmol) and NH 3 (5 mL) in CH 2 Cl 2 (10 mL). The crude product was used without further purification, yielding diaziridine 25 (469 mg, 1.07 mmol, quant.) as a white solid. R f (0.67, PE : EtOAc, 4:1); v max (cm -1 ) 2981 (C-H), 1457, 1157, 1036; mp 149-150 ; 1 HNMR (500 MHz, CDCl 3 ) " H 9.51 (1H, ddd, J = 8.5, 1.1, 1.1 Hz, H 9' ), 8.55 (1H, ddd, J = 8.6, 1.1, 1.1 Hz, H 4' ), 8.49 (1H, dd, J = 7.4, 1.1 Hz, H 2' ), 8.17 (1H, s, H 6 ), 7.92 (1H, dd, J = 7.4, 1.1 Hz, H 7' ), 7.73 (1H, dd, J = 8.6, 7.4 Hz, H 3' ), 7.70 (2H, s, H 2 and H 3 ), 7.55 (1H, dd, J = 8.5, 7.4 Hz, H 8' ), 2.91 (1H, d, J = 8.9 Hz, -NH), 2.34 (1H, d, J = 8.9 Hz, -NH); 13 CNMR (125 MHz, CDCl 3 ) " C 163.5 (C 7 ), 151.0 (C 4 ), 142.5 (C 5 ), 132.5 (C 5' ), 132.0 (C 10' ), 131.9 (C 4' ), 130.9 (C 7' ), 130.3 (C 2' ), 129.7 (C 1 ), 128.3 (C 8' ), 127.2 (C 1' ), 126.3 (C 3' or C 9' ), 126.2 (C 3' or C 9' ), 125.6 (C 2 ), 124.5 (q, 1 J C-F = 276.6 Hz, C 9 ), 123.6 (C 6' ), 120.8 (C 6 ), 110.9 (C 3 ), 58.3 (q, 2 J C-F = 36. CNMR (125 MHz, CDCl 3 ) " C 163.6 (C 7 ), 150.7 (C 4 ), 142.8 (C 5 ), 132.4 (C 5' ), 132.1 (C 10' ), 132.0 (C 4' ), 131.0 (C 7' ), 130.4 (C 2' ), 128.3 (C 8' ), 126.3 (C 3' ), 126.1 (C 9' ), 125.6 (C 1 ), 124.0 (C 2 ), 123.6 (C 1' or C 6' ), 123.4 (C 1' or C 6' ), 122.3 (q, Diazirine 4 was obtained according to General Procedure G, using diazirine 26 (200 mg, 0.465 mmol), bis(triphenylphosphine)palladium(II) dichloride (48.9 mg, 69.7 µmol), copper(I) iodide (8.86 mg, 46.5 µmol), NEt 3 (1.50 mL) and trimethylsilylacetylene (78.2 µL, 0.558 mmol) in THF (10 mL). The reaction was worked up after 6 h, although starting material was still present. The TMS-protected alkyne intermediate formed was purified by flash column chromatography (PE : EtOAc, 1:0 ae 99:1), then deprotected with TBAF (0.93 mL, 1 M in THF) in THF (5 mL). The reaction was complete after 30 min. The crude product was purified by flash column chromatography (pentane : toluene, 19:1) to yield alkyne 4 (58.9 mg, 0.156 mmol, 34%) as an o -white solid. CNMR (125 MHz, CDCl 3 ) " C 163.9 (C 7 ), 150.7 (C 4 ), 142.8 (C 5 ), 134.0 (C 5' ), 131.9 (C 7' ), 130.9 (C 4' ), 130.5 (C 2' ), 130.2 (C 10' ), 127.4 (C 9' ), 127.3 (C 8' ), 125.9 (C 3' ), 125.6 (C 1 ), 123.9 (C 2 ), 123.2 (C 1' ), 122.3 (q, 1 J C-F = 274.7 Hz, C 9 ), 120.6 (C 6' ), 119.4 (C 6 ), 111.1 (C 3 ), 82.7 (C 12' ), 81.5 (C 11' ), 28. 4-fluorobenzoyl chloride (18.6 g, 0.12 mol) was added to a suspension of 2-amino-4-bromophenol (20.0 g, 0.11 mol) in xylenes (100 mL) and refluxed for 1 h. Then methanesulfonic acid (2.0 g, 0.02 mol) was added and the mixture was refluxed for a further 1 h. The reaction was cooled to RT, diluted with EtOAc (500 mL) and washed with water, sat. aq. NaHCO 3 and brine. The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was recrystallized from petroleum ether/EtOAc (2:1) and filtered to a ord the title compound (20.0 g, 90% To a degassed solution of 5-bromo-2-(4-fluorophenyl)benzo [d] oxazole (20.0 g, 0.07 mol), ethylphosphinic acid (14.8 g, 0.14 mol) and DIPEA (25 mL, 0.14 mol) in DME (100 mL) and toluene (300 mL) Pd(OAc) 2 (0.92 g, 0.004 mol) and XantPhos (2.27 g, 0.004 mol) were added under N 2 and the reaction was stirred at 90°C for 2 h. The solvents were removed in vacuo and the residue partitioned between EtOAc and NaOH (1M). The aqueous layer was extracted into EtOAc, acidified with 1M HCl (pH 3) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 , and the desired product was obtained by column chromatography (5% MeOH/DCM) as an o -white solid (18.9 g, 86%). Figure S1 . Utrophin modulators such as heregulin, ezutromid and probe 3 increase fusion of DMD myoblasts into mature myotubes. a) Schematic of the process of fusion of proliferating myoblasts into myotubes. b) Immortalised DMD myoblasts were treated with compound or vehicle (0.1% DMSO) during five days of differentiation, then fixed and stained for utrophin (green), myosin heavy chain (red) and DAPI (blue). Images taken with a Perkin Elmer Operetta high-content imaging system with a 10 × objective; top: vehicle control, bottom: 10 μM ezutromid. c) Dose-dependent increase in fusion of myoblasts to mature myotubes after 5 days observed after heregulin and ezutromid treatment is also observed after treatment with probe 3, but not 2 or 4. Fusion index is shown (top) as mean ± SD and nuclei count (bottom) mean ± SD , each n = 4. Figure S2 . Second generation compound SMT022332 7 upregulates utrophin mRNA and protein levels, to a similar degree as the first generation compound ezutromid. a) Synthesis of second generation compound 7; chiral separation of racemic compound 8 yielded the two enantiomers. b) Ezutromid and 7 treatment (each 0.3 μM, 48 h incubation) increases utrophin mRNA expression (normalized to B2M), n = 6. * denotes p < 0.05, ** is p <0.005. c) SMT022332 increases utrophin protein expression comparable to ezutromid after 24 h of compound treatment in human DMD myoblasts, determined by Western blot. Bars represent means of utrophin expression normalised to total protein and relative to DMSO, error bars are standard error of the mean, n = 4, * denotes p < 0.05. Representative blot shown right, uncropped blot presented in Supplementary Fig. 8 CD44 antigen P15379;P15379-2;Q3U8S1;A2APM5;P15379-3;A2APM3;P15379-6;A2APM4;P15379-11;P15379-5;E9QKM8;Q80X37;P15379-10;P15379-9;P15379-4;A2APM1;P15379-8;P15379-7;A2APM2 P15379;P15379-2;Q3U8S1;A2APM5;P15379-3;A2APM3;P15379-6;A2APM4;P15379-11;P15379-5;E9QKM8;Q80X37;P15379-10;P15379-9;P15379-4;A2APM1;P15379-8;P15379-7;A2APM2 17. 2.10591 Gnai2;Gnao1;Gnas;Gnai3;Gnal;Gnat2;Gnat1;Gnat3;Gnai1 Guanine nucleotide-binding protein G(i) subunit alpha-2;Guanine nucleotide-binding protein G(o) subunit alpha;Guanine nucleotide-binding protein G(s) subunit alpha isoforms short;Guanine nucleotide-binding protein G(k) subunit alpha;Guanine nucleotide-binding protein G(olf) subunit alpha;Guanine nucleotide-binding protein G(t) subunit alpha-2;Guanine nucleotide-binding protein G(t) subunit alpha-1;Guanine nucleotide-binding protein G(s) subunit alpha isoforms XL P08752;P18872;P63094;Q9DC51;Q8CGK7;P50149;P20612;Q6R0H7;Q3V3I2;P18872-2;A2A610;A2AE31;A0A0A6YWA9;A2AE32;B2RSH2;Z4YKV1;P63094-2;Q66L47;Q6R0H7-4 P08752;P18872;P63094;Q9DC51;Q8CGK7;P50149;P20612;Q6R0H7;Q3V3I2;P18872-2;A2A610;A2AE31;A0A0A6YWA9;A2AE32;B2RSH2;Z4YKV1;P63094-2;Q66L47;Q6R0H7 Plectin Q9QXS1;Q9QXS1-3;Q9QXS1-6;Q9QXS1-15;Q9QXS1-10;Q9QXS1-9;Q9QXS1-12;Q9QXS1-11;Q9QXS1-13;Q9QXS1-5;Q9QXS1-16;Q9QXS1-4;Q9QXS1-14;Q9QXS1-7;Q9QXS1-8;Q9QXS1-2;E9Q3W4;F6R059;A0A0R4J223;E9Q9J6;A0A0R4J221;A0A0R4J218;E9PW24 Q9QXS1;Q9QXS1-3;Q9QXS1-6;Q9QXS1-15;Q9QXS1-10;Q9QXS1-9;Q9QXS1-12;Q9QXS1-11;Q9QXS1-13;Q9QXS1-5;Q9QXS1-16;Q9QXS1-4;Q9QXS1-14;Q9QXS1-7;Q9QXS1-8;Q9QXS1 
